ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2017
Secretases-related miRNAs in Alzheimer's disease: new approach for biomarker discovery.
Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Early detection of Alzheimer's disease using small RNAs. Results from the EPAD cohort.The journal of prevention of Alzheimer's disease · 2025Article
- The Analysis of Herpes Simplex Virus Type 1 (HSV-1)-Encoded MicroRNAs Targets: A Likely Relationship of Alzheimer's Disease and HSV-1 Infection.Cellular and molecular neurobiology · 2022Article
- MicroRNAs in Huntington's Disease: Diagnostic Biomarkers or Therapeutic Agents?Frontiers in cellular neuroscience · 2021Review
- Androgen Therapy in Neurodegenerative Diseases.Journal of the Endocrine Society · 2020Review
- Beta-Amyloid-Dependent miRNAs as Circulating Biomarkers in Alzheimer's Disease: a Preliminary Report.Journal of molecular neuroscience : MN · 2020Article
- Emerging Roles of Dysregulated MicroRNAs in Myasthenia Gravis.Frontiers in neuroscience · 2020Review
- Circulating MicroRNAs as Diagnostic Biomarkers for Motor Neuron Disease.Frontiers in neuroscience · 2020Review
- Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia.Frontiers in aging neuroscience · 2020Review
- Association of variants in microRNA with Parkinson's disease in Chinese Han population.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- MicroRNA-10a inhibits A30P α-synuclein aggregation and toxicity by targeting proapoptotic protein BCL2L11.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyloid-β (Aβ) as a crucial factor in pathogenesis of Alzheimer's disease (AD) is derived from amyloid precursor protein (APP) through a proteolytic process catalyzing by β- and γ-secretase-in amyloidogenesis pathway. Products of α-secretase cleavage also have protective effects against Aβ toxicity. According to existing evidences, microRNAs (miRNAs) show a unique pattern of expression in AD. Moreover, miRNAs regulatory effects on expression of secretases and their main components have been demonstrated in AD. The miRNAs levels may be changed in preclinical conditions and may be considered as diagnostic biomarkers in AD. Therefore, in this paper, we review the miRNAs involved in APP cleavage pathways and the formation of Aβ in order to evaluate the potential diagnostic biomarkers in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.